FIELD: medicine.
SUBSTANCE: invention relates to the treatment of liver cirrhosis. The use of a ligand-linked gold cluster is provided for the treatment of liver cirrhosis in a subject, wherein the ligand-linked gold cluster contains a gold core having a diameter in the range of 0.5–3 nm and a ligand associated with the gold core. The ligand is selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives and other thiol-containing compounds, where L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC) and N-acetyl-L-cysteine (L-NAC), and wherein D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D- cysteine (D-NIBC) and N-acetyl-D-cysteine (D-NAC); cysteine-containing oligopeptides and their derivatives are cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides; and other thiol-containing compounds selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L-proline, 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-D-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine and dodecylmercaptan.
EFFECT: use of the invention improves liver function.
5 cl, 2 tbl, 14 dwg
